Veracyte, Inc.
Veracyte operates as a diagnostics company offering tests for various cancers, including thyroid, prostate, breast, lung, and lymphoma. Products include Afirma, Decipher, Prosigna, Percepta, and Envisia. The company also develops the nCounter analysis system and LymphMark test.
Overview
Strengths
- Price to book ratio (1.84) is lower than the sector mean (9.96).
Weaknesses
- With a depreciation Potential of -51.31%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (89.83) is significantly higher than the sector mean (67.88).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- EV/EBIT (76.90) is significantly higher than the sector mean.
Key Financial Data
| Indicator | Value |
|---|
| PER | 89.8 |
| EV/EBITDA | 36.3 |
| Price/Free Cash Flow' | 34.0 |
| ROIC | 6.1% |
| Net Debt/EBITDA | 100.0 |